Resverlogix Corp. (TSX: RVX) is a global leader in developing safe, epigenetic therapeutics for people suffering from chronic illnesses. Lead drug apabetalone is the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation – for a major cardiovascular indication – to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy. Learn more about apabetalone, a first-in-class, small molecule that is a selective BET inhibitor that produces a specific set of biological effects with important benefits while maintaining a well described safety profile, currently being evaluated for the following indications:
For more information, visit company’s website: www.resverlogix.com
Register now to listen to Resverlogix’s presentation at the GCFF Virtual Conference on September 10th!
Donald McCaffrey | Co-founder, President and CEO
Donald McCaffrey is co-founder, President and CEO of Resverlogix Corp. Don has 40 years of corporate management experience including 20 years in drug discovery & development. Don is also the co-founder, President and CEO of Zenith Epigenetics, a private, clinical stage biotechnology company focused on novel cancer therapeutics.
September 10th, 2020 Thursday
8:30am – 1:30pm PST (11:30am – 4:30 EST)
Covering the healthcare, technology, fintech and cannabis sectors the GCFF Virtual Conference – Investing in Innovation will provide its participants with access to exciting investment opportunities that are at the cusp of value growth. The bilingual online event will feature 12 public and private company presentations and will broadcasted in both English and Mandarin Chinese channels. Register for our virtual event today!